An allegation that the Trump administration tried to secure exclusive rights to the production of an experimental coronavirus vaccine in Germany has revived health officials’ concerns that countries worldwide might move to nationalize key supplies to respond to the growing pandemic.

The allegation, first reported on Sunday in German media and later echoed by the nation’s health minister, centered on the suggestion that the Trump administration sought to strike a deal with CureVac, a drug maker that is based in the city of Tübingen but that also has operations in the United States.

Exactly what the Trump administration was offering, and how CureVac responded, was unclear. A U.S. official denied the reports, and the company’s main shareholders — including the Bill and Melinda Gates Foundation — immediately made clear CureVac’s vaccine would not be sold to a single country.

Credit: David TrinksRead more…